Literature DB >> 26201802

SNPs in the promoter region of the osteopontin gene as a possible host factor for sex difference in hepatocellular carcinoma development in patients with HCV.

Kazuhiro Hamaoka1,2, Sumiko Nagoshi1,2, Kayoko Sugawara1,2, Kayoko Naiki1,2, Yoshihito Uchida1,2, Mie Inao1,2, Nobuaki Nakayama1,2, Kenji Fujiwara1,2, Satoshi Mochida3,4.   

Abstract

AIMS: Four single nucleotide polymorphisms (SNPs) exist in the promoter region of the osteopontin (OPN) gene, namely, the SNPs at nucleotide (nt) -155, -616, and -1748 showing linkage disequilibrium to each other, and an independent SNP at nt -443. The significance of these SNPs in the risk of hepatocellular carcinoma (HCC) development was examined in patients with hepatitis C virus (HCV).
METHODS: The SNPs at nt -155 and nt -443 were analyzed in 120 patients with HCC. The promoter activity was measured in HepG2 cells by the dual-luciferase reporter assay. The electrophoretic mobility shift assay was performed using nuclear extracts from the cells.
RESULTS: Peripheral platelet counts at the time of HCC detection were greater in women with homozygous deletion at nt -155 and C/C or C/T at nt -443 than in those showing other allelic combinations, while no such difference was observed in men. The promoter activity was greater in oligonucleotides with deletions at nt -155 and C at nt -443 than in those with other haplotypes. The mobility shift assay showed double and single complexes with oligonucleotides around nt -155 and nt -443, respectively. Binding activities were greater in deletion than in G in the case of the retarded complex in the former assay and in T than in C in the latter assay. The other complex in the former assay included SRY, showing an equivalent binding activity to oligonucleotides with both alleles.
CONCLUSION: OPN promoter SNPs may play a role in the sexual difference in the risk of HCC development through the regulation of OPN expression in patients with HCV.

Entities:  

Keywords:  Hepatocellular carcinoma; Osteopontin; SNPs; SRY; Sex difference

Year:  2012        PMID: 26201802     DOI: 10.1007/s12072-012-9404-1

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  41 in total

1.  A study of goat SRY protein expression suggests putative new roles for this gene in the developing testis of a species with long-lasting SRY expression.

Authors:  Fatemeh Montazer-Torbati; Ayhan Kocer; Aurélie Auguste; Lauriane Renault; Gilles Charpigny; Eric Pailhoux; Maëlle Pannetier
Journal:  Dev Dyn       Date:  2010-12       Impact factor: 3.780

Review 2.  The regulation and role of osteopontin in malignant transformation and cancer.

Authors:  Mohamed K El-Tanani; Frederick Charles Campbell; Vittal Kurisetty; Dachuan Jin; Mella McCann; Philip S Rudland
Journal:  Cytokine Growth Factor Rev       Date:  2006-11-17       Impact factor: 7.638

3.  Sex- or gender-specific medicine in hepatology.

Authors:  Sumiko Nagoshi
Journal:  Hepatol Res       Date:  2007-11-28       Impact factor: 4.288

4.  Co-expression of osteopontin and CD44v9 in gastric cancer.

Authors:  T Ue; H Yokozaki; Y Kitadai; S Yamamoto; W Yasui; T Ishikawa; E Tahara
Journal:  Int J Cancer       Date:  1998-04-17       Impact factor: 7.396

5.  The implication of osteopontin (OPN) expression and genetic polymorphisms of OPN promoter in oral carcinogenesis.

Authors:  Yu-Wei Chiu; Hsi-Feng Tu; I-Kai Wang; Cheng-Hsien Wu; Kuo-Wei Chang; Tsung-Yun Liu; Shou-Yen Kao
Journal:  Oral Oncol       Date:  2010-03-09       Impact factor: 5.337

6.  Expression of the human SRY protein during development in normal male gonadal and sex-reversed tissues.

Authors:  L Salas-Cortés; F Jaubert; M R Bono; M Fellous; M Rosemblatt
Journal:  J Exp Zool       Date:  2001-11-01

7.  Expression of osteopontin in Kupffer cells and hepatic macrophages and Stellate cells in rat liver after carbon tetrachloride intoxication: a possible factor for macrophage migration into hepatic necrotic areas.

Authors:  R Kawashima; S Mochida; A Matsui; Y YouLuTuZ; K Ishikawa; K Toshima; F Yamanobe; M Inao; H Ikeda; A Ohno; S Nagoshi; T Uede; K Fujiwara
Journal:  Biochem Biophys Res Commun       Date:  1999-03-24       Impact factor: 3.575

8.  Osteopontin: possible role in prostate cancer progression.

Authors:  G N Thalmann; R A Sikes; R E Devoll; J A Kiefer; R Markwalder; I Klima; C M Farach-Carson; U E Studer; L W Chung
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

9.  Genetic polymorphims in promoter region of osteopontin gene may be a marker reflecting hepatitis activity in chronic hepatitis C patients.

Authors:  Satoshi Mochida; Michie Hashimoto; Atsushi Matsui; Masashi Naito; Mie Inao; Sumiko Nagoshi; Makoto Nagano; Tohru Egashira; Shunji Mishiro; Kenji Fujiwara
Journal:  Biochem Biophys Res Commun       Date:  2004-01-23       Impact factor: 3.575

10.  Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis.

Authors:  Jian Zhao; Li Dong; Bin Lu; Guobin Wu; Dongmei Xu; Jingjing Chen; Kai Li; Xin Tong; Jianxin Dai; Side Yao; Mengchao Wu; Yajun Guo
Journal:  Gastroenterology       Date:  2008-05-07       Impact factor: 22.682

View more
  2 in total

1.  A Genetic Variant of miR-34a Contributes to Susceptibility of Ischemic Stroke Among Chinese Population.

Authors:  Gui-Jiang Wei; Ming-Qing Yuan; Li-He Jiang; Yu-Lan Lu; Chun-Hong Liu; Hong-Cheng Luo; Hua-Tuo Huang; Zong-Quan Qi; Ye-Sheng Wei
Journal:  Front Physiol       Date:  2019-04-24       Impact factor: 4.566

2.  The Y-linked proto-oncogene TSPY contributes to poor prognosis of the male hepatocellular carcinoma patients by promoting the pro-oncogenic and suppressing the anti-oncogenic gene expression.

Authors:  Tatsuo Kido; Yun-Fai Chris Lau
Journal:  Cell Biosci       Date:  2019-03-04       Impact factor: 7.133

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.